Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Supporting evidence

• Evaluation report

• Final appraisal determination committee papers (PDF 1.07 MB)

  Published:

  19 September 2018

• Appraisal consultation committee papers (PDF 6.79 MB)

  Published:

  19 September 2018